Market Research Report
Coagulation Factor XI - Pipeline Review, H2 2019
|Published by||Global Markets Direct||Product code||363581|
|Published||Content info||70 Pages
Delivery time: 1-2 business days
|Coagulation Factor XI - Pipeline Review, H2 2019|
|Published: December 27, 2019||Content info: 70 Pages||
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 126.96.36.199) - Factor XI or plasma thromboplastin antecedent is the zymogen form of factor Xia. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Inhibitors of factor XIa include protein Z-dependent protease inhibitor.
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 188.8.131.52) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 11 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Hematological Disorders and Infectious Disease which include indications Thrombosis, Arterial Thrombosis, Bleeding And Clotting Disorders, Venous Thromboembolism, Venous (Vein) Thrombosis, Acute Ischemic Stroke, Hemophilia C (Factor XI Deficiency), Sepsis, Cerebral Infarction (Brain Infarction), Hemorrhagic Fever and Stroke.
The latest report Coagulation Factor XI - Pipeline Review, H2 2019, outlays comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 184.108.40.206) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 220.127.116.11) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.